(Total Views: 212)
Posted On: 09/26/2023 5:09:26 PM
Post# of 182
NetworkNewsBreaks – SOHM, Inc. (SHMN) Announces Acquisition of World-Class Gene-Editing Platform
SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.) According to the announcement, ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome. ABBIE will enable the editing of genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and engineering technologies. “ABBIE is a platform tool that delivers genes of interest for clinical trials,” said David Aguilar, PhD, SOHM’s COO who is leading ABBIE’s development. “Compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending. Our strategic partnerships and capital management have enabled us to streamline development and expedite our commercialization.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.) According to the announcement, ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome. ABBIE will enable the editing of genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and engineering technologies. “ABBIE is a platform tool that delivers genes of interest for clinical trials,” said David Aguilar, PhD, SOHM’s COO who is leading ABBIE’s development. “Compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending. Our strategic partnerships and capital management have enabled us to streamline development and expedite our commercialization.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
